Featured News
Traverse Biosciences Executes Exclusive, Worldwide License Agreement
Mar 16 2015
NEW YORK, NY
Traverse Biosciences, founded by Joseph Scaduto - one of the Center for Biotechnology's first BioEntrepreneurs-in-Residence, annou
Learn MoreMillennial Materials and Devices Presenting at NY Business Plan Competition FinalsApr 8 2015
Gaurav Lalwani, PhD, Biomedical Engineering department at Stony brook University and Center for Biotechnology Fundamentals Program
Learn MoreNew Mathematical Model May Improve Drug Discovery - Study Co-Authored by CFB's Dr. Eleanor AllenApr 22 2015
A new mathematical model that uses drug-target kinetics to predict how drugs work in vivo may provide a foundation to improve drug
Learn More-
Envisagenics Awarded $2M+ Direct to Phase II NCI SBIR GrantOctober 20, 2026
Envisagenics announced that it has been awarded a Direct to Phase II SBIR grant from the National Cancer Institute (NCI). The award will provide more than $2 million over two years to support further development and commercialization of SpliceCore®, including …
Learn More -
CFB Innovator Receives Seed Funding Through SUNY Technology Accelerator FundOctober 6, 2026
Congratulations to CFB Innovator and Stony Brook University Professor Dr. M. Hassan Arbab on securing an award from the SUNY Technology Accelerator Fund! The SUNY Technology Accelerator Fund (TAF) helps support critical research, such as feasibility studies, prototyping, and testing, …
Learn More -
Envisagenics Announces strategic multi-year collaboration with Boehringer IngelheimSeptember 28, 2026
Our colleagues at Envisagenics recently announced their strategic multi-year collaboration with Boehringer Ingelheim to advance the development of next-generation oncology therapies. This partnership brings together Envisagenics’ SpliceCore platform for the discovery and validation of novel tumor-specific targets with Boehringer’s expertise …
Learn More
Upcoming Events
No Events